<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Res Notes</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Res Notes</journal-id>
      <journal-title-group>
        <journal-title>BMC Research Notes</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1756-0500</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26987365</article-id>
      <article-id pub-id-type="pmc">4797229</article-id>
      <article-id pub-id-type="publisher-id">1975</article-id>
      <article-id pub-id-type="doi">10.1186/s13104-016-1975-9</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Barraquer&#x2013;Simons syndrome: a rare form of acquired lipodystrophy</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3053-0785</contrib-id>
          <name>
            <surname>Oliveira</surname>
            <given-names>Joana</given-names>
          </name>
          <address>
            <email>joana.ij.oliveira@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Freitas</surname>
            <given-names>Paula</given-names>
          </name>
          <address>
            <email>paula_freitas@sapo.pt</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lau</surname>
            <given-names>Eva</given-names>
          </name>
          <address>
            <email>evalau.med@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Carvalho</surname>
            <given-names>Davide</given-names>
          </name>
          <address>
            <email>davideccarvalho@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <aff id="Aff1"><label/>Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar S&#xE3;o Jo&#xE3;o, Alameda Prof. Hern&#xE2;ni Monteiro, 4200 Porto, Portugal </aff>
        <aff id="Aff2"><label/>Faculty of Medicine, University of Porto, Alameda Prof. Hern&#xE2;ni Monteiro, 4200 Porto, Portugal </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>18</day>
        <month>3</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>18</day>
        <month>3</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2016</year>
      </pub-date>
      <volume>9</volume>
      <elocation-id>175</elocation-id>
      <history>
        <date date-type="received">
          <day>18</day>
          <month>9</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>3</day>
          <month>3</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Oliveira et al. 2016</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>Human lipodystrophies are uncommon disorders, with important clinical consequences, which are often undiagnosed. The Barraquer&#x2013;Simons syndrome is a form of partial symmetric lipodystrophy of unknown etiology, characterized by the loss of subcutaneous adipose tissue, limited to upper part of the body. Insulin resistance and metabolic complications are less common than with other lipodystrophy subtypes. Patients usually have decreased serum complement-component 3 levels, associated with complement activation by the alternative pathway, which may indicate the presence of renal involvement.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>The authors report a case of a 31-year-old woman with progressive loss of subcutaneous fat, limited to the face, neck and thorax. She presented no severe metabolic complications, neither signs of insulin resistance. Laboratory tests revealed mild dyslipidemia, and low serum levels of complement-component 3. Clinical and biochemical characteristics were consistent with the diagnosis of Barraquer&#x2013;Simons syndrome.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>The present case illustrates the importance of recognizing the clinical features of this lipodystrophic syndrome, which may present potentially severe consequences and psychological distress. A brief overview is made, addressing the clinical signs of the disease, its course, and how to manage it.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Acquired partial lipodystrophy</kwd>
        <kwd>Barraquer&#x2013;Simons syndrome</kwd>
        <kwd>Cephalothoracic lipodystrophy</kwd>
        <kwd>Adipose tissue</kwd>
        <kwd>Hypocomplementemia</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2016</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p>Human lipodystrophies are a group of acquired or inherited disorders which are characterized by selective fat loss, ranging from partial to generalized [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Lipodystrophies are usually tightly linked with severe metabolic complications, which highlight the significance of adipose tissue as an active endocrine organ [<xref ref-type="bibr" rid="CR3">3</xref>]. Insulin resistance, diabetes mellitus, dyslipidemia, hypertension and hepatic steatosis are often seen in affected patients [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. The severity of metabolic disease usually correlates with the extent of fat loss, suggesting that insulin resistance could result from the absence of adipose tissue and the consequent leptin deficiency [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. More than a century ago, Mitchell [<xref ref-type="bibr" rid="CR6">6</xref>], Barraquer [<xref ref-type="bibr" rid="CR7">7</xref>], and Simons [<xref ref-type="bibr" rid="CR8">8</xref>] described the first lipodystrophic disorder, known as <italic>lipodystrophia progressiva</italic>, or Barraquer&#x2013;Simons syndrome, which is now called &#x2018;acquired partial lipodystrophy&#x2019; (APL). Approximately 250 patients have been described in the literature [<xref ref-type="bibr" rid="CR9">9</xref>], the majority being of European descent [<xref ref-type="bibr" rid="CR10">10</xref>]. Females are three to four times more likely to be affected than men [<xref ref-type="bibr" rid="CR11">11</xref>]. Fat loss usually starts during childhood or adolescence, and may follow an acute viral infection such as measles [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Barraquer&#x2013;Simons syndrome is mainly characterized by the loss of subcutaneous tissue, limited to upper part of the body, with the face, neck, arms, thorax, and upper abdomen being affected in a cephalocaudal manner (cephalothoracic lipodystrophy). In contrast, the adipose stores of the gluteal regions and lower extremities tend to be either preserved or are increased [<xref ref-type="bibr" rid="CR11">11</xref>]. Unlike others types of lipodystrophy, insulin resistance and its related metabolic complications appear to be less frequent (diabetes 10&#xA0;%, hypertriglyceridemia 30&#xA0;%) and are less severe [<xref ref-type="bibr" rid="CR13">13</xref>]. One third of patients presented membranoproliferative glomerulonephritis and associated signs of activation of alternative complement pathway&#x2014;the reduction of circulating concentrations of complement-component 3 (C3), and the presence of the C3-nephritic factor [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. The authors describe the clinical case of a female patient with clinical and biochemical features consistent with Barraquer&#x2013;Simons syndrome.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <sec id="Sec3">
        <title>Case description</title>
        <p>A 31-one-year old Caucasian woman was referred to the endocrinology department for a facial lipodystrophy. She was the second child of non-consanguineous, healthy parents. The neonatal period and her psychomotor development were unremarkable. She had chickenpox during her childhood, and later mumps at the age of fifteen. Her first menstruation was when she was 12&#xA0;years old, and she had had regular menstrual cycles ever since. At puberty, she noted that her subcutaneous adipose facial tissue gradually began to decrease (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). No abnormality in her past medical history existed, and she had never used any drug that could cause lipodystrophy. There was no family history of the same condition and furthermore, she did not report any symptoms. A physical examination revealed facial lipoatrophy, with loss of buccal fat pads and prominent zygomatic arches. She presented bilateral breast hypoplasia. The subcutaneous fat was preserved in other anatomic regions, particularly in the lower abdomen and thighs (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). She presented normal thyroid palpation. Hepatosplenomegaly, umbilical hernia, acanthosis nigricans, clitorimegaly, hirsutism or acromegalic features were all absent. Ophthalmic and other systemic examinations were unremarkable, including her neurological status and deafness was excluded. Laboratory tests, including a complete blood count, biochemical parameters (with renal and liver function tests), urine analysis with urinary albumin excretion, insulin-like growth factor-1 (IGF-1), and sexual and thyroid function tests revealed no abnormalities. Her fasting glucose (70, 82&#xA0;mg/dL) and insulin (2.7&#xA0;mU/mL), A1c (5.2&#xA0;%) and oral glucose tolerance test (2&#xA0;h plasma glucose 96&#xA0;mg/dL) presented normal values. There was a discrete elevation of LDL-cholesterol (139&#xA0;mg/dL), and reduced HDL-cholesterol (54&#xA0;mg/dL), with normal triglycerides level. The C3 levels were low, detected as &lt;18&#xA0;mg/dL (normal: 83&#x2013;177&#xA0;mg/dL). The patient presented no renal disease, nor more severe metabolic disorders up until our last observation. She underwent surgical correction of facial lipoatrophy, with good aesthetic results.<fig id="Fig1"><label>Fig.&#xA0;1</label><caption><p>Progressive facial lipoatrophy with loss of buccal fat pads</p></caption><graphic xlink:href="13104_2016_1975_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Fig.&#xA0;2</label><caption><p>Subcutaneous adipose tissue preserved in the lower abdomen and thighs</p></caption><graphic xlink:href="13104_2016_1975_Fig2_HTML" id="MO2"/></fig></p>
      </sec>
    </sec>
    <sec id="Sec4">
      <title>Discussion</title>
      <p>The overall clinical and biochemical features of our patient led us to consider Barraquer&#x2013;Simons syndrome as being the main diagnosis. The abnormal fat repartition was in conformity with the essential criterion proposed by Misra et al. [<xref ref-type="bibr" rid="CR12">12</xref>]: with gradual symmetrical subcutaneous fat loss from the face, neck, upper extremities, thorax and abdomen, preserving the lower extremities. Some supportive criteria were also met, namely: onset during adolescence, the absence of a family history of lipodystrophy, and low serum levels of C3. The lack of C3 allows for a clear distinction between this syndrome and other forms of lipodystrophy. The C3-nephritic factor induces lysis of adipocytes expressing factor D (adipsin)&#x2014;a serine protease enzyme&#x2014;and the overt expression of factor D by numerous tissues, which produces the characteristic fat loss pattern [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Some patients may progress to present drusen&#x2014;small accumulations of hyaline bodies underneath the retina [<xref ref-type="bibr" rid="CR17">17</xref>]. Such as in this present case, metabolic disorders can be absent in patients with late-onset partial lipodystrophy. Furthermore, acanthosis nigricans, hirsutism and signs of virilization are very unusual [<xref ref-type="bibr" rid="CR13">13</xref>].</p>
      <p>Mutations in several genes have been found in patients with inherited lipodystrophies, including mutations in <italic>LMNA</italic>, <italic>PPARG, AKT2</italic> and <italic>ZMPSTE24</italic> in partial lipodystrophy [<xref ref-type="bibr" rid="CR18">18</xref>], and mutations in <italic>AGPAT2, BSCL2, CAV1</italic> and <italic>PTRF</italic> in congenital total lipodystrophy [<xref ref-type="bibr" rid="CR19">19</xref>&#x2013;<xref ref-type="bibr" rid="CR21">21</xref>]. However, the molecular pathogenesis of APL has not been clearly established. In 2006, Hegele proposed that <italic>LMNB2</italic> could be a mutation responsible for APL. In four out of nine patients he found three new rare <italic>LMNB2</italic> mutations, by using candidate gene sequencing. He concluded that not all subjects with APL had <italic>LMNB2</italic> mutations and also found a few carrier mutations among healthy controls. Therefore, it seems that APL behaves like a complex trait, in which a susceptibility allele requires the presence of additional factors to trigger the expression of the disease [<xref ref-type="bibr" rid="CR22">22</xref>]. A family history is usually absent, and a broad set of autoimmune diseases is often associated [<xref ref-type="bibr" rid="CR17">17</xref>]: membranoproliferative glomerulonephritis, hypocomplementemia, systemic lupus erythematosus, dermatomyositis and localized scleroderma [<xref ref-type="bibr" rid="CR23">23</xref>&#x2013;<xref ref-type="bibr" rid="CR25">25</xref>]. Occasional functional anomalies, such as deafness, epilepsy, and mental retardation can also be associated with the condition [<xref ref-type="bibr" rid="CR26">26</xref>].</p>
      <p>Therapeutic approaches for APL consist of improving esthetic appearance with plastic surgery and the management of additional systemic disorders. The main goal of cosmetic surgical procedures is to minimize the psychological discomfort that impairs the patient&#x2019;s quality of life. Metabolic complications are not usually a main problem, however they still have to be screened and treated when they exist. A hypolipidic diet plan and regular exercise were advised, and medication will be offered when necessary. Thiazolidinediones stimulate growth and differentiation of adipocytes and seem to be effective in some heterogeneous forms of lipodystrophy. In 2003, Walker et al [<xref ref-type="bibr" rid="CR27">27</xref>] reported increases of fat in buccal and subcutaneous abdominal adipose tissue in a 20-year-old woman with APL after 7&#xA0;months of rosiglitazone therapy. Unfortunately, this may exacerbate the fat accumulation in non-affected regions. Recently, metreleptin, a recombinant analogue of human leptin, has been approved for the treatment of metabolic derangements of lipodystrophy. Metreleptin replaces the leptin deficiency, thus improving insulin resistance, hyperglycemia, dyslipidemia, and hepatic steatosis. Acquired partial lipodystrophy has less low leptin levels, and less metabolic derangements, and therefore metreleptin has lower efficacy [<xref ref-type="bibr" rid="CR28">28</xref>]. The prognosis of Barraquer&#x2013;Simons syndrome is mainly dependent on renal disease. A few patients have required renal transplantation for end-stage renal disease related to glomerulonephritis [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>].</p>
    </sec>
    <sec id="Sec5">
      <title>Conclusions</title>
      <p>Barraquer&#x2013;Simons syndrome is an extremely rare disorder with important clinical consequences and psychosocial effects. The authors underline the importance of the identification and the periodic assessment of patients with APL. Close long-term follow-up is required to identify metabolic disturbances, potentially life-threatening renal problems, and other associated diseases.</p>
    </sec>
    <sec id="Sec6">
      <title>Consent</title>
      <p>Written informed consent was obtained from the patient for publication of this Case Report and any accompanying images.</p>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>APL</term>
          <def>
            <p>acquired partial lipodystrophy</p>
          </def>
        </def-item>
        <def-item>
          <term>IGF-1</term>
          <def>
            <p>insulin-like growth factor-1</p>
          </def>
        </def-item>
        <def-item>
          <term>C3</term>
          <def>
            <p>plasma complement-component 3</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <ack>
      <title>Authors&#x2019; contributions</title>
      <p>JO collect the data and drafted the manuscript, EL helped to draft the manuscript, and PF and DC revised it critically for important intellectual content. All authors read and approved the final manuscript.</p>
      <sec id="FPar1">
        <title>Acknowledgements</title>
        <p>None.</p>
      </sec>
      <sec id="FPar2">
        <title>Competing interests</title>
        <p>The authors declare that they have no competing interests.</p>
      </sec>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Capeau</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Magre</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Caron-Debarle</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Human lipodystrophies: genetic and acquired diseases of adipose tissue</article-title>
          <source>Endocr Dev.</source>
          <year>2010</year>
          <volume>19</volume>
          <fpage>1</fpage>
          <lpage>20</lpage>
          <pub-id pub-id-type="doi">10.1159/000316893</pub-id>
          <pub-id pub-id-type="pmid">20551664</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garg</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Lipodystrophies: genetic and acquired body fat disorders</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2011</year>
          <volume>96</volume>
          <issue>11</issue>
          <fpage>3313</fpage>
          <lpage>3325</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2011-1159</pub-id>
          <pub-id pub-id-type="pmid">21865368</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nolis</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Exploring the pathophysiology behind the more common genetic and acquired lipodystrophies</article-title>
          <source>J Hum Genet</source>
          <year>2013</year>
          <volume>59</volume>
          <issue>1</issue>
          <fpage>16</fpage>
          <lpage>23</lpage>
          <pub-id pub-id-type="doi">10.1038/jhg.2013.107</pub-id>
          <pub-id pub-id-type="pmid">24152769</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gavrilova</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Marcus-Samuels</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Graham</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice</article-title>
          <source>J Clin Invest</source>
          <year>2000</year>
          <volume>105</volume>
          <fpage>271</fpage>
          <lpage>278</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI7901</pub-id>
          <pub-id pub-id-type="pmid">10675352</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reitman</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Arioglu</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Gavrilova</surname>
              <given-names>O</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Lipoatrophy revisited</article-title>
          <source>Trends Endocrinol Metab</source>
          <year>2000</year>
          <volume>11</volume>
          <fpage>410</fpage>
          <lpage>416</lpage>
          <pub-id pub-id-type="doi">10.1016/S1043-2760(00)00309-X</pub-id>
          <pub-id pub-id-type="pmid">11091118</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garg</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Lipodystrophies</article-title>
          <source>Am J Med</source>
          <year>2000</year>
          <volume>108</volume>
          <fpage>143</fpage>
          <lpage>152</lpage>
          <pub-id pub-id-type="doi">10.1016/S0002-9343(99)00414-3</pub-id>
          <pub-id pub-id-type="pmid">11126308</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>CA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Association of a homozygous nonsense caveolin-1 mutation with Berardinelli-Seip congenital lipodystrophy</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2008</year>
          <volume>93</volume>
          <fpage>1129</fpage>
          <lpage>1134</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2007-1328</pub-id>
          <pub-id pub-id-type="pmid">18211975</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Magre</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prevalence of mutations in AGPAT2 among human lipodystrophies</article-title>
          <source>Diabetes</source>
          <year>2003</year>
          <volume>52</volume>
          <fpage>1573</fpage>
          <lpage>1578</lpage>
          <pub-id pub-id-type="doi">10.2337/diabetes.52.6.1573</pub-id>
          <pub-id pub-id-type="pmid">12765973</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kumar</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Seema</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Aneja</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Partial lipodystrophy in a boy</article-title>
          <source>Indian Pediatr</source>
          <year>2000</year>
          <volume>37</volume>
          <fpage>93</fpage>
          <lpage>96</lpage>
          <pub-id pub-id-type="pmid">10745396</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fiorenza</surname>
              <given-names>Christina G</given-names>
            </name>
            <name>
              <surname>Chou</surname>
              <given-names>Sharon H</given-names>
            </name>
            <name>
              <surname>Mantzoros</surname>
              <given-names>Christos S</given-names>
            </name>
          </person-group>
          <article-title>Lipodystrophy: pathophysiology and advances in treatment</article-title>
          <source>Nat Rev Endocrinol.</source>
          <year>2011</year>
          <volume>7</volume>
          <issue>3</issue>
          <fpage>137</fpage>
          <lpage>150</lpage>
          <pub-id pub-id-type="doi">10.1038/nrendo.2010.199</pub-id>
          <pub-id pub-id-type="pmid">21079616</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ferrarini</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Milani</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bottigelli</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cagnoli</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Selicorni</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Two new cases of Barraquer&#x2013;Simons syndrome</article-title>
          <source>Am J Med Genet</source>
          <year>2004</year>
          <volume>126A</volume>
          <issue>4</issue>
          <fpage>427</fpage>
          <lpage>429</lpage>
          <pub-id pub-id-type="doi">10.1002/ajmg.a.20623</pub-id>
          <pub-id pub-id-type="pmid">15098243</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Misra</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Peethambaram</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Garg</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature</article-title>
          <source>Medicine (Baltimore).</source>
          <year>2004</year>
          <volume>83</volume>
          <fpage>18</fpage>
          <lpage>34</lpage>
          <pub-id pub-id-type="doi">10.1097/01.md.0000111061.69212.59</pub-id>
          <pub-id pub-id-type="pmid">14747765</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fardet</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Vigouroux</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Capeau</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Syndromes lipodystrophiques&#x2014;Lipodystrophies</article-title>
          <source>La Revue de m&#xE9;decine Interne.</source>
          <year>2013</year>
          <volume>34</volume>
          <fpage>614</fpage>
          <lpage>622</lpage>
          <pub-id pub-id-type="doi">10.1016/j.revmed.2012.11.008</pub-id>
          <pub-id pub-id-type="pmid">23287278</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eisinger</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Shortland</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Moorhead</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
          <article-title>Renal disease in partial lipodystrophy</article-title>
          <source>Q J Med.</source>
          <year>1972</year>
          <volume>41</volume>
          <fpage>343</fpage>
          <lpage>354</lpage>
          <pub-id pub-id-type="pmid">4561162</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peters</surname>
              <given-names>DK</given-names>
            </name>
            <name>
              <surname>Charlesworth</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Sissons</surname>
              <given-names>JG</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mesangiocapillary nephritis, partial lipodystrophy, and hypocomplementaemia</article-title>
          <source>Lancet</source>
          <year>1973</year>
          <volume>2</volume>
          <issue>7828</issue>
          <fpage>535</fpage>
          <lpage>538</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(73)92351-9</pub-id>
          <pub-id pub-id-type="pmid">4125297</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mathieson</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Wurzner</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Oliveria</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Lachmann</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Peters</surname>
              <given-names>DK</given-names>
            </name>
          </person-group>
          <article-title>Complement mediated adipocyte lysis by nephritic factor sera</article-title>
          <source>J Exp Med</source>
          <year>1993</year>
          <volume>177</volume>
          <fpage>1827</fpage>
          <lpage>1831</lpage>
          <pub-id pub-id-type="doi">10.1084/jem.177.6.1827</pub-id>
          <pub-id pub-id-type="pmid">8496694</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Misra</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Garg</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature</article-title>
          <source>Medicine (Baltimore).</source>
          <year>2003</year>
          <volume>82</volume>
          <fpage>129</fpage>
          <lpage>146</lpage>
          <pub-id pub-id-type="doi">10.1097/00005792-200303000-00007</pub-id>
          <pub-id pub-id-type="pmid">12640189</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Freitas</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Carvalho</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Lipodystrophy: beyond generalization?</article-title>
          <source>Panminerva Med</source>
          <year>2013</year>
          <volume>55</volume>
          <fpage>253</fpage>
          <lpage>268</lpage>
          <pub-id pub-id-type="pmid">24088799</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Delepine</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Boutet</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Association of a homozygous nonsense caveolin-1 mutation with Berardinelli-Seip congenital lipodystrophy</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2008</year>
          <volume>93</volume>
          <issue>4</issue>
          <fpage>1129</fpage>
          <lpage>1134</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2007-1328</pub-id>
          <pub-id pub-id-type="pmid">18211975</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hayashi</surname>
              <given-names>YK</given-names>
            </name>
            <name>
              <surname>Matsuda</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ogawa</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Human PTRF mutations cause secondary deficiency of caveolin resulting in muscular dystrophy with generalized lipodystrophy</article-title>
          <source>J Clin Invest.</source>
          <year>2009</year>
          <volume>119</volume>
          <issue>9</issue>
          <fpage>2623</fpage>
          <lpage>2633</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI38660</pub-id>
          <pub-id pub-id-type="pmid">19726876</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Subramanyam</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Simha</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Garg</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Overlapping syndrome with familial partial lipodystrophy, Dunnigan variety and cardiomyopathy due to amino-terminal heterozygous missense lamin A/C mutations</article-title>
          <source>Clin Genet</source>
          <year>2010</year>
          <volume>78</volume>
          <issue>1</issue>
          <fpage>66</fpage>
          <lpage>73</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1399-0004.2009.01350.x</pub-id>
          <pub-id pub-id-type="pmid">20041886</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hegele</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>DM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Sequencing of the reannotated <italic>LMNB2</italic> gene reveals novel mutations in patients with acquired partial lipodystrophy</article-title>
          <source>Am J Human Genet Vol</source>
          <year>2006</year>
          <volume>79</volume>
          <issue>2</issue>
          <fpage>383</fpage>
          <lpage>389</lpage>
          <pub-id pub-id-type="doi">10.1086/505885</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Payapvipapong</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Niumpradit</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Nakakes</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Buranawuti</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>A rare case of acquired partial lipodystrophy (Barraquer&#x2013;Simons syndrome) with localized scleroderma</article-title>
          <source>Int J Dermatol</source>
          <year>2014</year>
          <volume>53</volume>
          <fpage>82</fpage>
          <lpage>84</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-4632.2011.05435.x</pub-id>
          <pub-id pub-id-type="pmid">23675994</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jasin</surname>
              <given-names>HE</given-names>
            </name>
          </person-group>
          <article-title>Systemic lupus erythematosus, partial lipodystrophy and hypocomplementemia</article-title>
          <source>J Rheumatol</source>
          <year>1979</year>
          <volume>6</volume>
          <fpage>43</fpage>
          <lpage>50</lpage>
          <pub-id pub-id-type="pmid">439110</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Torrelo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Espana</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Boixeda</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ledo</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Partial lipodystrophy and dermatomyositis</article-title>
          <source>Arch Dermatol</source>
          <year>1991</year>
          <volume>127</volume>
          <fpage>1846</fpage>
          <lpage>1847</lpage>
          <pub-id pub-id-type="doi">10.1001/archderm.1991.04520010088019</pub-id>
          <pub-id pub-id-type="pmid">1845288</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Faguer</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A 10&#xA0;Mb duplication in chromosome band 5q31.3-5q33.1 associated with late-onset lipodystrophy, ichthyosis, epilepsy and glomerulonephritis</article-title>
          <source>Eur J Med Genet</source>
          <year>2011</year>
          <volume>54</volume>
          <fpage>310</fpage>
          <lpage>313</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejmg.2011.01.005</pub-id>
          <pub-id pub-id-type="pmid">21276880</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Walker</surname>
              <given-names>UA</given-names>
            </name>
            <name>
              <surname>Kirschfink</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Peter</surname>
              <given-names>HH</given-names>
            </name>
          </person-group>
          <article-title>Improvement of acquired partial lipodystrophy with rosiglitazone despite ongoing complement activation</article-title>
          <source>Rheumatology</source>
          <year>2003</year>
          <volume>42</volume>
          <fpage>393</fpage>
          <lpage>394</lpage>
          <pub-id pub-id-type="doi">10.1093/rheumatology/keg076</pub-id>
          <pub-id pub-id-type="pmid">12595651</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chong</surname>
              <given-names>AY</given-names>
            </name>
            <name>
              <surname>Lupsa</surname>
              <given-names>BC</given-names>
            </name>
            <name>
              <surname>Cochran</surname>
              <given-names>EK</given-names>
            </name>
            <name>
              <surname>Gorden</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Efficacy of leptin therapy in the different forms of human lipodystrophy</article-title>
          <source>Diabetologia</source>
          <year>2010</year>
          <volume>53</volume>
          <fpage>27</fpage>
          <lpage>35</lpage>
          <pub-id pub-id-type="doi">10.1007/s00125-009-1502-9</pub-id>
          <pub-id pub-id-type="pmid">19727665</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chopra</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Isaacs</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Mammen</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Pawar</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Renal transplantation in a patient with Barraquer&#x2013;Simons disease and mesangiocapillary glomerulonephritis type II</article-title>
          <source>Nephrol Dial Transplant</source>
          <year>2000</year>
          <volume>15</volume>
          <fpage>1723</fpage>
          <lpage>1724</lpage>
          <pub-id pub-id-type="doi">10.1093/ndt/15.10.1723</pub-id>
          <pub-id pub-id-type="pmid">11007867</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lenane</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Partial lipodystrophy and renal disease</article-title>
          <source>Clin Exp Dermato.</source>
          <year>2000</year>
          <volume>25</volume>
          <fpage>605</fpage>
          <lpage>607</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2230.2000.00717.x</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
